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Coxsackievirus B3 Infection Early in
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BACKGROUND: Coxsackievirus B (CVB) is the most common cause of viral myocarditis. It targets cardiomyocytes through coxsackie and adenovirus receptor, which is highly expressed in the fetal heart. We hypothesized CVB3 can precipitate congenital
heart defects when fetal infection occurs during critical window of gestation.
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METHODS AND RESULTS: We infected C57Bl/6 pregnant mice with CVB3 during time points in early gestation (embryonic day [E]
5, E7, E9, and E11). We used different viral titers to examine possible dose-response relationship and assessed viral loads in
various fetal organs. Provided viral exposure occurred between E7 and E9, we observed characteristic features of ventricular
septal defect (33.6%), abnormal myocardial architecture resembling noncompaction (23.5%), and double-outlet right ventricle
(4.4%) among 209 viable fetuses examined. We observed a direct relationship between viral titers and severity of congenital
heart defects, with apparent predominance among female fetuses. Infected dams remained healthy; we did not observe any
maternal heart or placental injury suggestive of direct viral effects on developing heart as likely cause of congenital heart defects.
We examined signaling pathways in CVB3-exposed hearts using RNA sequencing, Kyoto Encyclopedia of Genes and Genomes
enrichment analysis, and immunohistochemistry. Signaling proteins of the Hippo, tight junction, transforming growth factor-β1,
and extracellular matrix proteins were the most highly enriched in CVB3-infected fetuses with ventricular septal defects. Moreover,
cardiomyocyte proliferation was 50% lower in fetuses with ventricular septal defects compared with uninfected controls.
CONCLUSIONS: We conclude prenatal CVB3 infection induces congenital heart defects. Alterations in myocardial proliferate capacity and consequent changes in cardiac architecture and trabeculation appear to account for most of observed phenotypes.
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C

ongenital heart defects (CHDs) are the most
common anomalies in newborns, affecting 1 in
100 newborns annually.1 Although many lesions
are now treatable with excellent outcomes, still many
experience a shortened lifespan, whereas others endure lifelong residual cardiovascular problems,2 many
of whom continue to need invasive treatments and
not an insignificant number eventually requiring heart

transplantation.3 Pedigree analysis of families with
multiple affected individuals as well as other detailed
genetic studies have provided insights into the genetic
basis of several CHDs, and potential heterogeneous
pathogenic causes4; however, for a significant portion
of CHDs, the cause remains largely elusive.
Since the Rubella epidemic of 1964 in United States,
it has been recognized that viruses could play a role in
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CLINICAL PERSPECTIVE
What Is New?

• Our study found that maternal coxsackievirus B
(CVB) 3 infection during pregnancy caused various congenital heart defects, including ventricular septal defects, double-outlet right ventricle,
and ventricular noncompaction, as well as fetal
demise in a murine model.
• Infection during the critical E7 through E9 period
of gestation resulted in the highest incidence of
congenital heart defects in fetuses, with infection at E9 in particular effecting the greatest
impact.
• CVB3 suppresses cardiomyocyte proliferation
through stimulation of the transforming growth
factor-β1 pathway.

What Are the Clinical Implications?
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• Although CVB3 is a well-known cause of viral
myocarditis, evidence about its role in the
pathogenesis of congenital heart disease has
been scarce; CVB3 infection during pregnancy
represents a previously unknown cause behind
congenital heart defects and may account for
a significant number of cases without a clear
causative agent.
• Further studies assessing the role of maternal
CVB3 infection in babies with congenital heart
defects are needed to corroborate our findings
in humans.
• Epidemiological measures aimed at reducing
and preventing CVB3 infection in women of
reproductive age may reduce the incidence of
congenital heart disease.

Nonstandard Abbreviations and Acronyms
CAR
CVB
DORV
E
KEGG
TGF
VP1

coxsackievirus and adenovirus receptor
coxsackievirus B
double-outlet right ventricle
embryonic day
Kyoto Encyclopedia of Genes and
Genomes
transforming growth factor
viral capsid protein

cause of many birth defects, including CHDs.5,6 Some
of these studies suggest a strong association between
viral infections and fetal congenital anomalies of the
nervous and cardiovascular systems.7 Overall, prenatal infections are presumed to account for 2% to 3%
of all congenital anomalies, most often by infections
with “TORCH” organisms: toxoplasmosis, rubella,

cytomegalovirus, herpes, and “other.”8 The latter category of “other” pathogens is continually expanding: for
example, a high incidence of congenital defects has
been reported in infants born coincident with seasonal
influenza epidemics and Zika virus infection during
early pregnancy.9,10
Coxsackievirus B (CVB) infects 10 million US citizens annually, allowing for a potentially large exposure burden. Six serotypes (B1–B6) are recognized,
with serotypes B2, B3, and B4 considered endemic
in the United States, and serotypes B1 and B5 exhibiting epidemic patterns.11 Coxsackievirus and adenovirus receptor (CAR; encoded by CXADR in humans) is
believed to be the primary mediator of CVB infection,
serving as a point for attachment and internalization for
all CVB serotypes.12 CXADR is expressed in the human
placenta during the first trimester,13 and transplacental transfer of CVB is well documented in humans,14
suggesting the potential for exposure of the developing
fetus to viral infections. Evidence of CVB infection in
late gestation mouse placenta and fetus is seen within
2 to 3 days of maternal infection, with a short duration
of fetal viremia (2–4 days).15 That the developing heart
can be a target for virus-induced pathological features
is also suggested from studies showing that following
perinatal maternal infection with CVB, viral RNA is detected in the neonatal heart for up to 5 days16 and is
associated with damage in neonatal cardiomyocytes.17
Studying serologic responses, Brown and Evans
(1967) were the first to suggest a possible clinical association of early gestation maternal CVB infection with
various congenital heart and brain defects, later posited by others as well.18-21 No further studies, however,
have provided direct evidence that CVB causes CHD
or a plausible mechanism to account for the clinical
observations.
We have hypothesized that infection by “cardiotropic” viruses (ie, viruses, such as CVB, that enter the
cardiomyocyte via specific receptors in the fetal heart)
can induce CHD by interfering with normal cardiomyocyte proliferation, provided infection occurs during a
critical window (first trimester) of cardiogenesis. To
test our hypothesis, we used a mouse model to examine fetal exposure to CVB in early gestation. We
also examined the influence of sex in this mechanism
because prior studies have suggested sex differences
in susceptibility to infection by CVB, as well as in the
incidence of certain CHDs.22,23

METHODS
The authors declare that all supporting data are available within the article (and its online supplementary
files), and any additional information is available from
the corresponding author on reasonable request.
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Propagation of Coxsackievirus and
Infectivity Assays

Downloaded from http://ahajournals.org by on February 22, 2022

LLC-MK2 derivative cells (American Type Culture
Collection CCL-7.1) were maintained in minimum
essential medium (Corning-Mediatech, 10-009CV) containing 10% fetal bovine serum (Millipore,
TMS-013-B) and 2 mmol/L (1×) GlutaMAX-I (Gibco,
35050-061) at 37°C in a 5% CO2 incubator. CVB3,
Nancy (American Type Culture Collection, VR-30)
was propagated in monolayers of LLC-MK2, derivative cells. When cytopathic effect reached 95%
to 100%, virus stocks were prepared by subjecting
cells and media to 3 freeze-thaw cycles, clarifying
the media by centrifugation (2800g, 10 minutes) and
aliquoting the supernatant. Aliquots were quick frozen on dry ice and stored at −80°C. Virus concentration was determined using an end point dilution
assay on LLC-MK2, derivative cells and expressed
as a 50% tissue culture infective dose per milliliter, as
calculated by the Spearman and Kärber algorithm.24
To determine the presence of infectious virus, fetal
tissues were homogenized in serum-free minimal
essential media containing penicillin, streptomycin,
and amphotericin B. The suspension was frozen on
dry ice, quickly thawed at 37°C, and then clarified
by centrifugation at 2000g for 10 minutes. A portion
of the supernatant was used to inoculate LLC-MK2
derivative cells seeded the day prior in 24-well plates.
Cultures were observed daily for the presence of cytopathic effect for at least 1 week. Live cells remaining on the plates following the observation period
were fixed with 4% paraformaldehyde and stained
with 0.1% crystal violet.

Experimental Animals
C57Bl6/J mice were purchased from The Jackson
Laboratory and allowed to acclimate for 1 week before any procedures. Animal protocols were approved
by the Institutional Animal Care and Use Committee
at Washington University School of Medicine (protocol No. 20170070). All procedures conformed to
the guidelines from the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Matings were set up overnight, and the following
morning, considered embryonic day (E) 1, the females were examined for the presence of a copulation plug. Weights were monitored throughout the
gestation period, and weight gain was used as an
indicator of the progression of pregnancy and maternal health after infection. Pregnant females were
randomly assigned into either a control group (n=7)
or groups inoculated by intraperitoneal injection with
the virus (n=42) at the selected gestational day. We
used a matrix with 4 time points of CVB3 infection
(E5, E7, E9, and E11) and 3 viral inoculation doses
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(1 × 10 6, 2.5 × 10 6, and 5 × 10 6 50% tissue culture
infective dose). Dams were observed daily following
inoculation for signs of illness (ie, lethargy and rough
coat). Fetoplacental units from all groups were collected by laparotomy under general anesthesia at the
desired gestational stage. Dams were euthanized by
exsanguination and cardiectomy under inhaled 5%
isoflurane anesthesia. Placental and fetal tissues
were either flash frozen, embedded in optimal cutting
temperature compound (Tissue-Tek, 4583), and then
frozen or fixed in 4% paraformaldehyde and embedded in paraffin for immunohistochemical analysis.
The fetuses were collected at E15 to E17, as normal
cardiac formation would be complete and, hence,
any abnormalities identified would not be residua of
incomplete development.

Histological Analysis and
Immunohistochemistry
Transverse serial 7-µm sections of the mouse fetus
and placenta were stained with hematoxylin and eosin
to assess heart morphological features. Maternal
heart sections were stained with Masson trichrome
stain to detect cardiac injury. Sections for immunohistochemistry were deparaffinized and rehydrated,
and then antigen retrieval was performed using
the citrate-based solution (H-3300) and high temperature-pressure protocol of Vector Laboratories
(Burlingame, CA). Samples were blocked for 1 hour
at room temperature with 10% fetal bovine serum
and then incubated overnight at 4°C with primary
antibodies PHH3 (Millipore 06-570) to identify mitotic cells, MF20 (Developmental Studies Hybridoma
Bank, MF20) to identify myocytes, and Mouse AntiEnterovirus Clone 5-D8/1 (Dako M7064) to identify
CVB VP1 (viral capsid protein) region. For immunofluorescence detection, sections were incubated
with Alexa Fluor–conjugated secondary antibodies
(Invitrogen, goat anti-rabbit IgG No. A11011 and goat
anti-mouse IgG No. A11001) for 2 hours at room
temperature. Slides were mounted with Vectashield
mounting media with 4′,6-diamidino-2-phenylindole
(Vector Labs, H-1200) and imaged using a Zeiss fluorescent microscope (Axiovert with Apotome 2 apparatus). Apoptosis in the experimental groups was
assessed in a blinded manner by terminal deoxynucleotidyl transferase dUTP nick end labeling staining
using the In Situ Cell Death Detection Kit, TMR red
(Roche 12156792910), according to manufacturer’s
instructions.

Placental Histological Features
Placental sections obtained from infected and uninfected groups were processed for histological analysis. Hematoxylin and eosin staining was performed on
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sections, as per standard protocol. Placental sections
(n=3–4) of the decidua, junctional zone, and labyrinth
zone from each group were examined in a blinded manner (C.J. and I.M.) for evidence of pathological features.

Fetal Heart Culture
Fetal hearts were collected at E11 from uninfected and
CVB3 infected (E9) dams and cultured on Millicell EZ
8-well slides (Millipore Sigma PEZGS0816) in highglucose DMEM (American Type Culture Collection
30-2002) supplemented with 10% fetal bovine serum
(Millipore TMS-013-B), 1% penicillin-streptomycin
(Gibco 15140-122), and 1% amphotericin B (Corning
30-003-CF). Cells were grown for 3 days, to achieve
an age comparable to E14 gestation, and fixed with
paraformaldehyde for immunohistochemistry.

Mouse Fetal Sex Determination
Genomic DNA was extracted from frozen tissue
using Tissue Direct polymerase chain reaction (PCR)
kit (Lamda Biotech D300-100), amplified using Taq
Polymerase 2× PCR premix (Intact Genomics, 3249)
and SX primers (SX_forward, 5ʹ-GATGATTTGAGTGG
AAATGTGAGGTA-3ʹ; SX_reverse, 5ʹ-CTTATGTTTATAG
GCATGCACCATGTA-3ʹ),25 and the PCR products were
analyzed on a 2% agarose gel.
Downloaded from http://ahajournals.org by on February 22, 2022

Determination of Cell Proliferation
Cell proliferation in fetal hearts was determined by mitotic index, which was expressed as the percentage of
pHH3 stained nuclei in MF20-positive cardiomyocytes/
total number of nuclei in MF20-positive cardiomyocytes. Cell counting was calculated in 4 biological replicates using ImageJ image processing software (US
National Institutes of Health).26 Individual data points
together with the average measurements are reported
as the mean±SD.

RNA Extraction
RNA extraction was done using QIAamp Viral RNA
mini kit (Qiagen 52904) for reverse transcription–PCR
and Arcturus PicoPure RNA isolation kit (Applied
Biosystems 12204-01) for quantitative PCR and sequencing using manual guidelines. cDNA synthesis
was done using SuperScript III First-Stand (Invitrogen
18080-051) and RT All-in-One master mix (Lamda
Biotech G208-100). For sequence analysis, RNA was
extracted from fetal tissues embedded in optimal cutting temperature; tissues were sectioned at 10 µm onto
polyethylene naphthalate membrane slides (Leica,
11505158). Fetal heart tissue was collected using a
Leica LMD7000 Laser Microdissection System from
CVB3-infected fetuses, showing a ventricular septal
defect (VSD) and uninfected control fetuses.
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PCR Analysis
End point PCR was done using EV primers (forward,
CGGCCCCTGAATGCGGCTAATCC; reverse, TTG
TCACCATAAGCAGCCA).27 PowerUp SYBR Green
Mastermix (Applied Biosystems A25741) was used
for quantitative PCR to quantify CVB (forward,
CCCCGGACTGAGTATCAATA; reverse, GCAGTTAG
GATTAGCCGCAT),28 Transforming growth factor
(TGF)-β1 (forward, CAACAATTCCTGGCGTTACCTTGG;
reverse, GAAAGCCCTGTATTCCGTCTCCTT), GAPDH
(forward, GCATGGCCTTCCGTGTTC; reverse, GATGTCAT
CATACTTGGCAGGTTT),29 BMP2 (bone morphogenetic
protein 2) (forward, TGTGGGCCCTCATAAAGAAGCAGA;
reverse, AGATCCCTGCTTCTCAAAGGCACT),30 Mothers
against decapentaplegic homolog 1 (Smad1; forward, CGCTCCACGGCACAGTTAAG; reverse, GCCA
GTTGATTTGCGAACAGAA), Mothers against de
capentaplegic
homolog
5
(Smad5;
forward,
TGCAGCTTGACCGTCCTTACC; reverse, GCAGACC
TACAGTGCAGCCATC), and Mothers against decapentaplegic homolog 9 (Smad9; forward,
CGATCATTCCATGAAGCTGACAA; reverse, TGGGCA
AGCCAAACCGATA).31

RNA Sequencing
RNA was extracted from the heart tissue and submitted to the Genome Technology Access Center
(Department of Genetics at Washington University
in St. Louis) to perform RNA sequencing using
next-generation sequencing for transcriptome profiling. Total RNA integrity was determined using an
Agilent Bioanalyzer. Library preparation was performed with 10 ng of total RNA with a Bioanalyzer
RNA integrity number score >8.0. Double-stranded
cDNA was prepared using the SMARTer Ultra Low
RNA kit for Illumina Sequencing (Takara-Clontech),
per manufacturer’s protocol. cDNA was fragmented
using a Covaris E220 sonicator using peak incident
power 18, duty factor 20%, and cycles per burst 50
for 120 seconds. cDNA was blunt ended, had an A
base added to the 3’ ends, and then had Illumina
sequencing adapters ligated to the ends. Ligated
fragments were then amplified for 12 to 15 cycles
using primers incorporating unique dual index tags.
Fragments were sequenced on an Illumina HiSeq
3000 with single-end 50 base-pair reads. Basecalls
and demultiplexing were performed with Illumina’s
bcl2fastq software and a custom python demultiplexing program with a maximum of one mismatch
in the indexing read. RNA-sequencing reads were
then aligned to the Ensembl release 76 top-level
assembly with STAR version 2.0.4b.32 Gene counts
were derived from the number of uniquely aligned
unambiguous reads by Subread:featureCount version 1.4.5.33 Isoform expression of known Ensembl
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transcripts was estimated with Sailfish version
0.6.13.34 Sequencing performance was assessed
for the total number of aligned reads, total number
of uniquely aligned reads, and features detected.
The ribosomal fraction, known junction saturation,
and read distribution over known gene models were
quantified with RSeQC version 2.3.35
All gene counts were then imported into the R/
Bioconductor package EdgeR,36 and trimmed mean
of M values normalization size factors were calculated to adjust for samples for differences in library
size. Genes or transcripts not expressed in any sample were excluded from further analysis. The trimmed
mean of M values size factors and the matrix of
counts were then imported into the R/Bioconductor
package Limma.37 Weighted likelihoods based on the
observed mean-variance relationship were then derived for every gene with Voom.38 The performance
of all genes was assessed with plots of the residual
SD of every gene to their average log count with a
robustly fitted trend line of the residuals. Differential
expression analysis was then performed to analyze
for differences between conditions, and the results
were filtered for only those genes with BenjaminiHochberg false-discovery rate adjusted P≤0.05.
The Kyoto Encyclopedia of Genes and Genomes
(KEGG) database was used to identify biological
pathways linked to differentially expressed genes enriched in CVB3-infected fetal hearts. For each contrast extracted with Limma, global perturbations in
known Gene Ontology terms and KEGG pathways
were detected using the R/Bioconductor package
GAGE39 to test for changes in expression of the reported log 2 fold changes reported by Limma in each
term versus the background log 2 fold changes of
all genes found outside the respective term. The R/
Bioconductor packages heatmap340 and Pathview41
were used to display heat maps or annotated KEGG
graphs across groups of samples for each Gene
Ontology term or KEGG pathway, respectively, with
a Benjamini-Hochberg false-discovery rate adjusted
P≤0.05.
Data have been deposited to Gene Expression
Omnibus (accession No. GSE157522).

Statistical Analysis
Two-sample t test was used to compare the differences between control and test groups when the
outcomes are continuous, and χ2 test was used to
compare the differences between control and test
groups when the outcomes are categorical. P≤0.05
was considered statistically significant. For multiple
biological replicates, SD was calculated. To quantify
amount of virus in tissue samples, standard curve
equation was used along with its coefficient of
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determination (R2). Differences in observed phenotypes between sexes were compared using a logistic regression, with outcomes reported as odds ratio
(95% CI). Statistical analysis was performed using
SPSS 27.0 (IBM Corporation, Armonk, NY).

RESULTS
CVB3 Passes From Infected Pregnant
Dam Into the Fetuses
To demonstrate passage of CVB3 from the infected
mother to the developing fetus, initially we performed
infectivity assay and end point PCR on fetal lysates
(Figure 1A and 1B). To confirm the presence of virus
within the fetus (and to localize the viral particles), we
made multiple attempts at RNA in situ hybridization
without success. We, therefore, used quantitative
PCR not only to confirm the presence of the virus but
also to quantify the viral load within the fetus. Using a
standard curve based on our CVB3 stock (Figure 1D),
we measured CVB3 levels in placenta (Figure 1E)
and various fetal organs (Figure 1F) at different time
points (E11, E14, and E17) following inoculation at E9.
These data show that high levels of virus persist for
at least 6 days within the placenta. CVB3 quantification in different fetal organs was done with specific emphasis on those that express CAR. Because
dissection of individual organs was not possible at
E11, we elected to divide the fetus into head (brain),
midtorso (heart), and lower torso (liver and intestine)
segments for analysis at that gestational age. At E14,
we examined heart, brain, midtorso (predominantly
liver), and lower torso. At E17, we could dissect out all
individual organs. We found the maximum amount of
CVB3 in the fetal heart at E14, followed by fetal brain
at E17 (Figure 1F).
We also performed immunohistochemistry to detect VP1 on both fetal tissue sections and explanted
hearts (at E11) that were cultured for 3 days (~E14).
Although the anti-VP1 antibody did not reliably detect
the virus in tissue sections of the fetal hearts, with in
vitro culture we could easily detect VP1, confirming the
continued presence of the virus in the hearts of fetuses
from CVB3 infected dams (Figure 1C).

Maternal CVB3 Infection Leads to
Abnormal Heart Development in Fetal Mice
At E17, approximately one third of the fetuses from
CVB3 infected dams were either dead or resorbed
(37.2%; n=124/333; P=0.001) and could not be
processed for assessment of heart morphological features (Figure 2A and 2F). Of the 209 infected
fetuses assessed, 78 (37.3%; P=0.00002) had one
or multiple CHDs: 66 (31.6%; P=0.0005) exhibited
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Figure 1. Vertical transmission of coxsackievirus B (CVB) 3 from infected pregnant dams to the fetus.
A, The presence of infectious virus in fetal lysates from infected and uninfected dams (embryonic day [E] 9) was analyzed using a cell
culture infectivity assay; the lack of stained cells indicates the presence of virus. B, Reverse transcription–polymerase chain reaction
(PCR) with enterovirus (EV)–specific primers, showing amplification of the 149-bp (determined by agarose gel electrophoresis) virus
band only in the tissue lysate of a fetus from an infected dam (at E9). C, Immunohistochemistry using anti-EV antibody on cultured
fetal heart (~E14) explanted at E11 from a dam infected at E9 (white arrows). Virus quantification by quantitative PCR. D, Standard
curve based on the concentration of CVB3 stock. E, Virus present in placenta at E11, E14, and E17 after infection at E9 (n=6 for each
gestational age). F, Virus present in fetal organs at E11, E14, and E17 after infection at E9 (n=6 for each gestational age). To quantify the
amount of virus in tissue samples, the standard curve equation was used along with its coefficient of determination (R2). Bar=20 µm.
TCID50 indicates 50% tissue culture infective dose.
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VSD (Figure 2C and 2F; Figure S1a-c for more representative sections), 48 (23%; P=0.00002) exhibited
alteration in myocardial architecture grossly resembling noncompaction of the ventricular myocardium
(Figure 2D and 2F; Figure S1d-f for more representative sections), and 9 (4.3%; P=0.2) exhibited doubleoutlet right ventricle (DORV) phenotype (Figure 2E
and 2F). Of all the VSDs seen, most were perimembranous in nature and only 6% were muscular VSDs
(Figure S1a). The viral loads determined in the fetuses
showed resorbed fetuses had the highest viral loads
per milligram tissue, followed by fetuses with multiple CHDs, and the lowest load was seen in those
with isolated VSD or noncompaction (Figure 2 table).
Immune response was examined in fetal heart section using cluster of differentiation 45 antibody, which
showed no difference between infected and control
fetuses (data not shown). Part of resorbed fetus and
lower torso of fully formed fetuses were used to assess viral load. No other major heart pathological
feature was noted.

E7 to E9 Is the Critical Window for CVB3
Induction of CHDs in Fetal Mice
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Because expression of CAR, the receptor for CVB,
is essential between E10 and E11 for cardiomyocyte
development,42 we determined the time in gestation when CVB infection had the greatest impact
on the incidences of the induced CHD phenotype,
based on the timeline of mouse cardiac development
(Figure 3A). The highest proportion of fetuses exhibiting VSDs occurred after infection at E9, regardless of
the viral dose, with even low doses of CVB3 infection
leading to abnormal heart development (Figure 3B;
P=0.00001). The same pattern was observed for fetuses with noncompaction and DORV, with more incidences observed after infection at E9 for all CVB3
doses (Figure S2). Similarly, although fetal resorption occurred following CVB infection at each gestational stage, the most cases followed infection at E9
(Figure 3C; P=0.00001).

CHD Is Attributable to Direct Effect of
CVB Infection on the Fetuses
To confirm the CHDs observed were a direct effect
of CVB infection of the fetuses as opposed to poor
health of the moms or placental pathological features, we evaluated maternal health and examined
placental histological features. Infected dams did not
show outward signs of illness, such as lethargy or
rough coat following CVB3 infection. We compared
maternal weight gain before and after infection between infected dams and uninfected control dams
and found equivalent weight gain between the 2
groups (data not shown). Masson trichrome staining
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of maternal heart tissue from control and infected
dams also showed no evidence of myocarditis or
cardiac injury (Figure 4A through 4F). Placentas from
control and E9 infected fetuses collected at E11 and
E17 were analyzed by hematoxylin and eosin staining
and examined blindly by placental biology experts
(C.J. and I.M.). No placental damage, insufficiency,
or vascular injury was identified (Figure 4G through
4L). These results suggest the observed CHDs are
likely not simply a result of poor maternal health or
placental insufficiency.

CVB3 Stimulates the TGF-β1 Signaling
Pathway and Suppresses Cardiomyocyte
Proliferation
We found the maximum amount of CVB3 at E14
(Figure 1F); therefore, we used this time point for
KEGG enrichment analysis of differentially expressed
transcripts in VSD-exhibiting CVB3-infected and
uninfected fetal hearts. Transcriptome analysis detected 13,118 protein-coding genes in the fetal heart,
and differentially expressed genes were mapped to
determine which were upregulated or downregulated because of CVB3 infection (Gene Expression
Omnibus accession No. GSE157522) (Figure S3). The
top 5 pathways most significantly enriched in CVB3infected hearts (log fold change >1.9; P<0.05) were
those in the Hippo signaling, tight junction, TGF-β1,
cell cycle, and extracellular matrix receptor pathways
(Figure 5A). Numbers of genes upregulated in these
individual pathways were as follows: 4 of 118 genes
in Hippo signaling, 3 of 119 genes in tight junction, 7
of 61 genes in TGF-β1, and 10 of 61 genes in extracellular matrix receptor pathways.
Because increased TGF-β1 expression has been
reported in several CVB3 infection-related models,43
and because the expression of TGF-β1 transcript has
been found in regions actively undergoing cardiac
septation in murine embryos,44 we examined whether
the expression of other members of the TGF-β superfamily, known to be associated with cardiogenesis,
was altered. Quantitative PCR was used to validate
differentially expressed genes, and the findings were
consistent with data obtained by RNA sequencing. In
particular, we found upregulation of genes and transcripts encoding TGF-β1, BMP2, and downstream
mediators SMAD1/5/9 in fetal hearts with VSDs
(Figure 5B).
We assessed cell proliferation and apoptosis at E11,
focusing on a developmental time point before septal
completion (E13.5) (Figure 3A). We also examined E17
fetal heart sections to determine if the effects of CVB3
infection on proliferation were temporary or persistent.
In heart sections stained with an antibody against
phosphorylated histone H3, a marker for mitosis, cell
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Figure 2. Coxsackievirus B (CVB) 3 infection of pregnant dams leads to fetal cardiac defects and death.
A, Representative images of embryonic day (E) 17 fetuses from CVB3-infected dams, exhibiting specific phenotypes (left to right):
viable, fully formed dead, and 3 images showing fetuses at various stages of resorption. B–E, Hematoxylin and eosin–stained heart
sections of E17 fetuses from uninfected (B) and infected dams (C–E), and the various cardiac defects are indicated. F, Graph showing
the percentage of fetuses from CVB3-infected dams with the indicated cardiac defects. The χ2 test was used to analyze statistical
significance between control and test groups by calculating P values. Table showing the amount of virus present in resorbed fetuses
and fetuses with congenital heart defect (CHD), determined by quantitative polymerase chain reaction using CVB3 quantification
standard curve (Figure 1d). Part of resorbed fetus and lower torso of fully formed fetuses were used to assess viral load. Bar=100 µm.
Ao indicates aorta; DORV, double-outflow RV; LV, left ventricle; NC, noncompaction; RV, right ventricle; TCID50, 50% tissue culture
infective dose; and VSD, ventricular septum defect.

proliferation in fetuses infected at E9 and collected at
E11 and E17 was significantly lower than that in control fetuses with a mitotic index of 7.8% versus 15.8%
at E11 and 9.1% versus 36.6% at E17 (P=0.0006 and
P=0.0002, respectively) (Figure 5C through 5E). Cell
apoptosis levels, assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling staining, were
similar in CVB3-infected and control fetuses (data not
shown).

Female Mouse Fetuses Appear More
Susceptible to CVB3-Induced CHDs Than
Males

Downloaded from http://ahajournals.org by on February 22, 2022

Because sex differences have been reported in the
prevalence of congenital anomalies and specific cardiac defects,45 we examined whether there were differences based on sex with CVB3-induced CHDs.
We found more female fetuses developing CHDs
than males, although not reaching statistical significance (Figure 6). A 1.5-fold higher (P=0.1) VSD incidence among females was observed compared with
males. Females appeared also more susceptible to
DORV and noncompaction after CVB3 infection than
males, with a 3.4-fold (P=0.1) and a 1.4-fold (P=0.2)
increase, respectively. Furthermore, 1.2-fold (P=0.4)
more female fetuses were resorbed compared with
males following in utero CVB3 infection, suggestive
of perhaps greater susceptibility of the female fetuses to infection.

DISCUSSION
Viral infections in early pregnancy are recognized as
important factors that can affect cardiovascular development ever since an association between intrauterine rubella infection and CHD was first reported
in humans >45 years ago.46 Similarly, suggestive,
although inconclusive, evidence had been reported
associating coxsackievirus infection during pregnancy and CHDs.47 In the current study, we show
conclusively prenatal CVB3 infection can induce
CHDs, confirming prior suspicions based on epidemiologic studies (Figure 7I). Moreover, we find viral
load to directly relate to both severity and incidence
of fetal pathological features, showing highest viral

loads in the resorbed fetuses, followed by fetuses
with multiple CHDs, and lowest virus levels in fetuses
with isolated CHDs. The major heart defect observed
in our study, occurring in ~30% of fetal mice exposed
to CVB in utero, was perimembranous VSD, one of
the most prevalent CHDs in humans. Although not
the focus of our study, it is of interest the second fetal
organ where we identified abundant levels of CVB3
was the brain. Some studies have suggested the cooccurrence of central nervous system pathological
conditions with CHDs, although often these are attributed to secondary effects of altered in utero circulation from the primary CHD. Last, we identified a
critical window during mouse development (between
E7–E9) when prenatal CVB3 infection has the greatest impact on inducing heart defects (Figure 7I).
Prior reports using late gestation fetal mice suggested concentrations of CVB3 in fetal tissues peak
at approximately 3 days following maternal infection.48 We observed a similar pattern and therefore
speculate maternal CVB3 infections between E7 and
E9 in our experiments resulted in peak viral concentrations in the fetal heart around E10 to E12, when
septation of the primitive cardiac tube is completing.
Exposure of the fetal heart shortly before or during
the period of septation could explain the temporal
and quantitative relationship between CVB3 infection and the incidence of VSD that we observed in
fetal mice. Because we did not observe any obvious
placental injury and because the infected moms remained healthy throughout pregnancy, we suspect
the heart defects resulted directly from infection of the
fetus rather than secondary to placental insufficiency
or poor maternal health. Although not every maternal
heart was analyzed by Masson trichrome staining,
there are reports stating that C57BL/6 mice are less
susceptible to CVB3-induced myocarditis compared
with mice from other genetic backgrounds.49 Our
viral quantification studies suggest the placenta does
perform a superb job at filtering much of the viral
wave. Some viruses, however, clearly manage to get
across the placenta and persist for some time in the
fetus, with preferential proliferation in certain tissues
(eg, heart and brain).
It is of interest we also observed abnormal trabeculations and myocardial architecture resembling
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Figure 3. The effect of viral dose and gestational age at infection on the incidence of ventricular
septal defect (VSD) and fetal demise.
A, Schematic representation of the timeline of heart development in the mouse and critical window
for coxsackievirus B (CVB) 3 infection. B and C, Dams were infected at various stages of gestation
(embryonic day [E] 5, E7, E9, or E11) with different doses of virus (1.0, 2.5, and 5.0 × 106 50% tissue culture
infective dose). Graphs and their corresponding tables show the percentage of fetuses with VSDs (B) and
nonviable (dead or resorbed) fetuses (C) along with the total examined in each experimental group. The χ2
test was used to analyze statistical significance between control and test groups by calculating P values.

noncompaction in CVB3-infected fetal hearts. Non
compaction of the left ventricle, diagnosed in some
children with CHD,50 can be isolated or associated with
other congenital cardiac malformations. Although the
cause of noncompaction is presently unknown, noncompaction of the left ventricle is attributed to arise
from the arrest of the normal myocardial maturation
process during ontogenesis, with familial or genetic
triggers.51 Despite some controversy about diagnosis
of noncompaction, most agree noncompaction is a
genetically and phenotypically heterogeneous disease
that can affect both ventricles, and has been associated with several genetic variants as well as mutations

in cytoskeletal and sarcomeric proteins.52 Although our
data showing that ≈25% of CVB3-infected fetal hearts
develop abnormalities of trabeculation somewhat similar to noncompaction, perhaps attributable to CVB3mediated arrested myocardial development, additional
studies are required to correlate our findings to those
observed in the clinical setting as well as potential
mechanisms involved.
We examined signaling pathways to obtain insights into the molecular mechanisms responsible
for the observed phenotypes in our mice, focusing on differentially regulated genes as a result of
CVB3 infection. Enrichment of genes encoding for

J Am Heart Assoc. 2021;10:e017995. DOI: 10.1161/JAHA.120.01799510

Sharma et al

Coxsackievirus B3 Induces Congenital Heart Defects

A

B

C

D

E

G
Downloaded from http://ahajournals.org by on February 22, 2022

I

F

H

J

K

L

M

N

Figure 4. Cardiac defects in fetuses are not secondary to poor maternal health.
A–F, Masson trichrome–stained heart sections of uninfected control (n=5) (A) and infected dam (n=5)
(B). Higher magnifications of control right ventricle (RV) (C), control left ventricle (LV) (D), infected RV (E),
and infected LV (F) show no evidence of cardiac injury. G–N, Hematoxylin and eosin–stained placental
sections of embryonic day 17 fetuses from uninfected (n=10) (G) and infected dams (n=10) (H). Higher
magnifications of control (I, J, and K) and infected (L, M, and N) tissue show no evidence of placental
damage in different parts of placenta. Bar=1000 µm. De indicates decidua; IVS, interventricular septum;
JZ, junctional zone; and LZ, labyrinth zone.

components of the TGF-β1 signaling pathway in
fetuses with CVB3-induced heart defects, like elevated expression of BMP2 and its downstream signaling transcription factors, Smad 1, 5, and 9, may
be related to observed VSD as well as altered trabeculation patterns in our mice. Increase in TGF-β1
expression is associated with cardiomyopathies in

general but also with CVB3-induced dilated cardiomyopathy.43,53 A critical role for BMP signaling in
cardiac development has been extensively studied;
deletion of Bmp2 from the endocardial lineage results in perimembranous VSDs in mouse embryos.54
Moreover, upregulation of BMP2 in the cardiac fields
phosphorylates SMAD1/5/9, and enhanced SMAD
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Figure 5. The effect of coxsackievirus B (CVB) 3 infection on different signaling pathways and cell proliferation.
A, Top 5 differentially regulated Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathways in heart tissue from
embryonic day (E) 14 fetuses infected with CVB3 at E9. B, Comparison of RNA-sequencing (black dot, n=4) and quantitative reverse
transcription–polymerase chain reaction (white dot, n=4) data for upregulated genes within the pathways (transforming growth factor
[TGF]-β1, BMP2 [bone morphogenetic protein 2], Smad1, Smad5, and Smad9), normalized to Gapdh expression in heart tissue
from E14 fetuses infected with CVB3 at E9. C, pHH3-stained cells (individual data points as white dots and mean as black dot±SD),
indicating lower cell proliferation in the CVB3-infected fetal hearts (E11 and E17) compared with uninfected controls (n=4 for each
gestational age). D and E, Immunofluorescence images showing 4′,6-diamidino-2-phenylindole (DAPI)–stained DNA (blue), MF20stained cardiomyocytes (green), and pHH3-stained proliferating cells (red) in the E11 control and infected fetuses (D) and E17 control
and infected fetuses (E) (magnified images of the white box in the panels on the left). The number of stained cells was determined using
ImageJ software. The images are representative of 4 biological replicates. Bar=100 µm. ECM indicates extracellular matrix.
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Figure 6. Difference in incidence of observed defects following coxsackievirus B (CVB) 3 infection based on sex.
The percentage of fetuses from CVB3-infected dams exhibiting the indicated abnormal phenotype. Differences in observed phenotypes
between sexes were compared using a logistic regression, with outcomes reported as odds ratio (95% CI). CHD indicates congenital
heart defect; DORV, double-outflow right ventricle; NC, noncompaction; and VSD, ventricular septal defect.

signaling suppresses cell proliferation.55 We found
CVB3 suppressed cardiomyocyte proliferation in
the fetal heart, suggesting it is one of the possible

reasons behind observed phenotypes in our mice,56
and the resultant septation (VSD) and alignment defects (DORV) (Figure 7II).

Downloaded from http://ahajournals.org by on February 22, 2022
Figure 7. Mouse model of coxsackievirus B (CVB) 3 infection during pregnancy and proposed mechanism for ventricular
septal defect (VSD) formation after infection.
I, Mouse model of CVB virus infection during pregnancy, leading to vertical transmission of virus from infected pregnant mice to the
fetus, resulting in 3 outcomes: fetal death, congenital heart defect, and no cardiac phenotype. IIa–c, The proposed mechanism of
VSD generation. Normal intraventricular septum (IVS) formation (a), with the proliferation of the muscular IVS and the outflow tract
septum, resulting in a fully formed septum (b), is shown (proliferating cardiomyocytes are shown in green). c, In CVB-infected fetuses,
cell proliferation is suppressed, which leads to incomplete septum formation and VSD. LA indicates left atrium; LV, left ventricle; RA,
right atrium; and RV, right ventricle.
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KEGG pathway enrichment analysis also showed
that genes in the Hippo signaling pathways, known
to regulate cardiovascular development and function,
were enriched in CVB3-infected fetal hearts compared
with uninfected controls. The Hippo signaling pathway
is conserved across species and has a critical role in
regulating embryonic organ (including heart) size and
cardiomyocyte cell proliferation and apoptosis.57 Our
observations of altered fetal cardiomyocyte proliferative
capacity are therefore consistent with upregulation of
Hippo in our model. We also found expression of tight
junction signaling pathways to be enriched in fetal hearts
exposed to CVB3. Of note, the receptor for CVB3, CAR,
is highly expressed in the developing murine heart, and
CAR knockouts result in embryonic lethality from cardiac defects if expression is repressed during a critical
developmental window (E10 and E12).42 This critical
window coincides with the time at which fetal hearts in
our model would be exposed to the highest levels of
CVB3 following maternal infection at E7 to E9. Although
our transcriptomic data showed equal expression of
CAR and zonula occludens-1 in CVB3-infected and
uninfected heart tissue (data not shown), we plan to
pursue further analysis of these pathway components.
With regard to all transcriptomic studies, it is critical that
changes at the protein level may still occur without seeing a change in transcript levels. In totality, however, our
RNA-sequencing data do suggest CHD observed in our
model is likely related to alterations in proliferation capacity of fetal cardiomyocytes from CVB3 infection.
Sex hormones are thought to affect the susceptibility or response to CVB3 infection as well as CVB3induced myocarditis in adult mice. In the preceding
studies, males show more susceptibility to effects
of infection than females.58 Moreover, testosterone
has been shown to alter cardiac remodeling during
CVB3-induced myocarditis.59 We observed some
semblance of sex-influenced differences as well, albeit the reverse of preceding observations; however,
despite the rather large number of fetuses examined,
our observed ratios did not reach statistical significance. Clinicians and epidemiologists have reported
unequal sex distribution of various cardiac defects
in clinical cohorts,23,35 although frequently with conflicting results: equal male/female ratios for VSD, but
higher DORV incidence in males than females,60 versus in results from a large Dutch study of 4110 adults
with CHD, the incidence of VSD was higher among
females (53%) than males.61 Female fetuses are often
overrepresented in stillbirth and recurrent miscarriage cases.62 We are interested to further dissect the
influence of sex in our model in future studies as likely
these subtle differences reflect as of yet not understood but important mechanisms.
In conclusion, although birth malformations
caused by maternal viral infections, such as

Coxsackievirus B3 Induces Congenital Heart Defects

congenital rubella syndrome and those by the Zika
virus, have been well documented,10 we present
novel data that maternal infection with a common
enterovirus (CVB) can also result in development of
structural heart defects. We found differential regulation between the uninfected and CVB-infected
fetal hearts of signaling pathways associated with
cardiac development. On the basis of these findings,
we posit BMP/SMAD2 signaling-led suppressed
cardiomyocyte proliferation as one possible mechanism of CHD pathogenesis associated with CVB
infection. We believe our findings could have simple
but important implications from the perspective of
possible public health measures to reduce the incidence of CHD if clinical observations corroborate
our findings.
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Figure S1. Coxsackievirus B3 (CVB3) infection of pregnant dams leads to ventricular septal
defect (VSD) and non-compaction (NC).
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Hematoxylin and eosin-stained heart sections of E17-fetuses from infected dams with indicated
cardiac defects: muscular VSD (a), perimembranous VSD (b, c), NC (d, e, f). RV = right ventricle;
LV = left ventricle; VSD = ventricular septum defect; NC = non-compaction. Scale 100µm.

Figure S2. The effect of viral dose and gestational age on infection on the incidence of noncompaction (NC) and double outlet right ventricle (DORV).

Dams were infected at various stages of gestation (E5, E7, E9 or E11) with different doses of virus
Downloaded from http://ahajournals.org by on February 22, 2022

(1.0, 2.5 and 5.0x106 Tissue Culture Infective Dose (TCID) 50). Graphs show the percentage of
fetuses with NC (a) and DORV (b) of the total examined in each experimental group.

Figure S3. Expression heat map of up- and down-regulated mouse fetal heart genes at E14
comparing controls and Coxsackievirus B3 (CVB3)-infected fetuses.
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All 13,118 protein-coding genes detected by RNA-Seq analysis were plotted using the color blue
for down-regulation and red for up-regulation between and control (left 4 panels) CVB3-infected
(right 4 panels) groups.

